From: Fauci, Anthony (NIH/NIAID) [E]

Sent: Mon, 4 May 2020 21:05:39 +0000

To: Conrad, Patricia (NIH/NIAID) [E]

Subject: FW: Invitation to join (virtually) the ACTIV Leadership Meeting 5/6

## Please see me about this.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone:
(b) (6)
FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6) >

Sent: Monday, May 4, 2020 11:18 AM

To: ICDDIR-L@LIST.NIH.GOV

Cc: Parker, Ashley (NIH/OD) [E] (b) (6); Wholley, David (FNIH) [T]

(b) (6) >; Melencio, Cheryl (FNIH) [T] (b) (6) >

Subject: Invitation to join (virtually) the ACTIV Leadership Meeting 5/6

## Dear Colleagues,

As you may be aware, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership has been moving forward rapidly to address the global pandemic. We held our initial ACTIV leadership meeting on April 3<sup>rd</sup> including, NIH, FDA, BARDA, EMA, and industry heads of research and development. Four working groups were formed out of this meeting to focus on preclinical therapeutics, clinical therapeutics, clinical trial capacity, and vaccines.

Although some ICs have representatives participating in the working groups, we recognize there is a need to keep everyone looped in to the various activities and progress of the partnership, particularly in view of all of the concurrent IC projects about COVID-19. The ACTIV working groups will be delivering their second report to the ACTIV Leadership Group on Wednesday, May 6, from 3:30-5:00pm. I am writing to invite the ICDs to listen-in on this meeting. There will be a lot to cover during the meeting and the members of the Leadership Group will be asking the questions. But to give a chance for us NIHers to